Search clinical trials for: Dosing 1: Atomoxetine

Total 18780 results

Apnimed

Completed

Study for Efficacy and Dose Escalation of AD313 + Atomoxetine (SEED) (SEED)

Obstructive Sleep Apnea

United States
Spectrum Pharmaceuticals, Inc

Terminated

Study of Poziotinib in Japanese Patients With NSCLC

NSCLC

Japan
AstraZeneca

Completed

A Randomized, Open Label Study to Compare the Current Phase II and Planned Phase III Capsule Formulation of AZD6244 (AZD6244Formula)

Healthy Volunteers

United States
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Active, not recruiting

T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With HER2-Positive CNS Tumors (iCAR)

Brain Tumor, Recurrent | Brain Tumor, Refractory

United States
Seoul National University Hospital
Kyung Hee University Hospital at Gangdong

Completed

Efficacy and Safety of Midodrine and Atomoxetine for Neurogenic OH

Neurogenic Orthostatic Hypotension

Korea, Republic of
Norwegian University of Science and Technology
St. Olavs Hospital; Alesund Hospital; Namsos Hospital; Volvat Medisinsk Senter...

Recruiting

Bariatric Surgery and Pharmacokinetics of Atomoxetine

Obesity, Morbid

Norway
Eli Lilly and Company

Completed

An Italian Study of the Efficacy of Atomoxetine in the Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD) and Comorbid Oppositional Defiant Disorder (ODD).

Attention Deficit Hyperactivity Disorder | Oppositional Defiant Disorder

Italy
Eli Lilly and Company

Completed

A Long Term Study of a Medication for Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder

Spain, France, Austria, Germany, Belgium, Finland, Italy, Netherlands, Portugal, Sweden, Switzerland, United Kingdom
University of Florida
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Completed

Strength Training in Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy

United States
Johnson & Johnson Vision Care, Inc.

Completed

Clinical Evaluation of Investigational Contact Lenses

Visual Acuity

Hong Kong
McMaster University
Epitome Pharmaceuticals

Terminated

Randomized Controlled Feasibility Trial of the Fearon Algorithm to Improve Management of Unstable Warfarin

Hypoprothrombinemia

Canada
University of California, Los Angeles
National Institute on Drug Abuse (NIDA)

Terminated

Safety Assessment of Atomoxetine With MA IV Administration

Methamphetamine Dependence | Methamphetamine Abuse

United States
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

The Study of Ammoxetine Hydrochloride Enteric-coated Tablets in Subjects With Depression (Ammoxetine)

Major Depressive Disorder (MDD)
Brigham and Women's Hospital

Not yet recruiting

Pharyngeal Muscle Control Mechanisms of Atomoxetine-plus-oxybutynin in Obstructive Sleep Apnea

OSA

United States
Phost'In Therapeutics

Recruiting

First-in-human Trial of PhOx430, a First-in-class Acetylglucosaminyltransferase V Inhibitor, in Advanced Solid Tumours (PhAST)

Glioblastoma Multiforme | Metastatic Cancer | Advanced Solid Tumor | Malignant Tumor

Italy, France
Lindner Center of HOPE
University of Cincinnati

Completed

Atomoxetine in the Treatment of Binge Eating Disorder

Binge-eating Disorder

United States
Xijing Hospital

Unknown

Near-infrared Spectroscopy Neurofeedback as a Treatment for Children With Attention Deficit Hyperactivity Disorder

Attention Deficit Hyperactivity Disorder (ADHD) | Neurofeedback

China
Poitiers University Hospital

Terminated

Atomoxetine in Patients With Tourette's Syndrome (ATO-TS)

Tourette Syndrome

France
NYU Langone Health
Eli Lilly and Company

Completed

Atomoxetine/Attention Deficit/ Hyperactive Disorder (ADHD)/Substance Use Disorder (SUD)in a Residential Treatment Facility

Attention Deficit Hyperactivity Disorder
Yale University
National Institute on Drug Abuse (NIDA)

Completed

Atomoxetine Effects in Humans

Physiological Stress
Peking University

Unknown

Associated Genes With Atomoxetine Response in Attention Deficit Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder

China
Central Institute of Mental Health, Mannheim
Heidelberg University

Completed

Driving in Adults With Attention-deficit/Hyperactivity Disorder (ADHD) Before and During Treatment With Atomoxetine (DrivPerfATX)

Attention Deficit Hyperactivity Disorder

Germany
Eli Lilly and Company

Completed

An Open-Label Study of Atomoxetine in Adolescents With Attention-Deficit/Hyperactivity Disorder

Attention Deficit Hyperactivity Disorder

Germany
Eli Lilly and Company

Completed

An Open-Label Study of Atomoxetine in Children With Attention-Deficit/Hyperactivity Disorder

Attention Deficit Hyperactivity Disorder

Germany
Eli Lilly and Company

Completed

Maintenance of Benefit With Atomoxetine Hydrochloride in Adolescents With ADHD

Attention-Deficit/Hyperactivity Disorder

United States
Rhode Island Hospital
Eli Lilly and Company

Unknown

Effect of Atomoxetine on ADHD-Related Insomnia in Children and Adolescents

Insomnia | Attention-Deficit/Hyperactivity Disorder (ADHD)

United States
Assistance Publique - Hôpitaux de Paris

Completed

Benefits and Tolerance of Exercise in Patients With Generalized and Stabilized Myasthenia Gravis (MGEX)

Myasthenia Gravis

France
National Institute on Drug Abuse (NIDA)
University of Pennsylvania

Completed

Atomoxetine for the Treatment of Cannabis Dependence

Cannabis Dependence

United States
Eli Lilly and Company

Completed

Treatment With Atomoxetine Hydrochloride in Children and Adolescents With ADHD

Attention-Deficit/Hyperactivity Disorder | Comorbid Dyslexia

United States
Eli Lilly and Company

Completed

Study of Atomoxetine in Children With ADHD to Assess Symptomatic and Functional Outcomes

Attention-Deficit/Hyperactivity Disorder

Canada
Eli Lilly and Company

Completed

Open-Label Trial of Atomoxetine to Evaluate Academic Outcome in Children Ages 8-11 Years With Attention Deficit/Hyperactivity Disorder

Attention Deficit Hyperactivity Disorder

Canada
Alesi Surgical Ltd.

Unknown

Feasibility of the Ultravision™ System in Low Pressure Laparoscopic Cholecystectomy Compared to Airseal® IFS

Laparoscopic Cholecystectomy

United States
Eli Lilly and Company

Completed

Efficacy, Tolerability, and Safety of Once-Daily Atomoxetine Hydrochloride Versus Placebo in Russian Children and Adolescents With Attention-Deficit/Hyperactivity Disorder

Attention Deficit Disorder With Hyperactivity

Russian Federation
Cairo University

Completed

Clinical and Radiographic Evaluation of Crestal Bone Loss Around Implant With or Without Platform Switching Design (PS)

Crestal Bone Loss
Eli Lilly and Company

Completed

Atomoxetine Versus Placebo in Children With Attention Deficit/Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder

Japan
Eli Lilly and Company

Completed

Atomoxetine vs Placebo in the Treatment of ADHD in Swedish Children and Adolescents

Attention Deficit Hyperactivity Disorder

Sweden
Boehringer Ingelheim

Recruiting

A Study to Test Different Ways to Measure the Effect of Atomoxetine on Impulsive Behavior in Young Adults With Attention Deficit Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder

Germany
Apnimed

Completed

Trial of AD113 and Atomoxetine in OSA Patients With Hypertension

Hypertension | Obstructive Sleep Apnea

United States
New York State Psychiatric Institute
National Institute on Drug Abuse (NIDA)

Completed

Atomoxetine for Treating Marijuana-Abusing Adolescents Who Have Attention Deficit Hyperactivity Disorder

Marijuana Abuse | Attention Deficit Disorder With Hyperactivity

United States
Massachusetts General Hospital
National Institute on Drug Abuse (NIDA); National Institutes of Health (NIH)

Withdrawn

Efficacy of Atomoxetine for ADHD in Adolescents and Young Adults With SUD

Substance Use Disorder | Attention Deficit Hyperactivity Disorder

United States
Monarch Medical Research
Eli Lilly and Company

Terminated

Atomoxetine for Children With Acquired Attentional Disorders Following Completion of Chemotherapy for ALL

Attention Deficit Hyperactivity Disorder

United States
Rhode Island Hospital

Completed

The Effect of a Once Daily Dose of Atomoxetine (ATX) on ADHD-Related Insomnia in Children and Adolescents

Insomnia | Attention Deficit Hyperactivity Disorder

United States
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy, Safety, and Tolerability of LNA043 in Patients With Knee Osteoarthritis (ONWARDS)

Osteoarthritis

Taiwan, Spain, United Kingdom, United States, Argentina, Australia, Denmark, India, China, Czechia, Canada, Japan, Poland, Mexico, Estonia
Wake Forest University Health Sciences

Terminated

Fluid Resuscitation in Septic Shock Patients With BMI Elevation (FRISSBE)

Sepsis | Obesity | Septic Shock

United States
Apnimed

Completed

Crossover Trial of AD036 in Obstructive Sleep Apnea

Obstructive Sleep Apnea

United States
Eli Lilly and Company

Completed

Effects of Atomoxetine on Brain Activation During Attention & Reading Tasks in Participants With ADHD & Comorbid Dyslexia

Attention Deficit Hyperactivity Disorder | Dyslexia

United States
University of Calgary
Cardiac Arrhythmia Network of Canada

Completed

Prevention of Syncope Trial 6 - Atomoxetine in Vasovagal Syncope (POST6)

Vasovagal Syncope

Canada
Massachusetts General Hospital
Eli Lilly and Company

Completed

Strattera Treatment in Adults With Attention Deficit Hyperactivity Disorder Not Otherwise Specified (ADHD NOS)

ADHD NOS

United States
Craig Hospital

Completed

Efficacy Study of Strattera for Treating Attention Disorders in Traumatic Brain Injury (TBI)

Traumatic Brain INjury

United States
Eli Lilly and Company

Completed

A Long Term Follow-Up Study for Asian Adult Patients With Attention Deficit Hyperactivity Disorder

Attention Deficit Hyperactivity Disorder

Japan

Search clinical trials for: Dosing 1: Atomoxetine

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritius

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations